FIGURE S6


A
Concentration ruxolitinib (μM)
1500
1000
500
0
0 4 8 12 16 21 25
Weeks
Concentration ruxolitinib (μM)
3000
2000
1000
0
0 8 16 25 33
Weeks
B
% Vehicle control
100
50
0
-1.5 -1 0 1
Tofacitinib (log μM)
**
CMS resistant 1
CMS resistant 2
CMS parental
% Vehicle control
100
50
0
-1.5 -1 0 1
Tofacitinib (log μM)
*
M-07e resistant
M-07e parental
C
CMS
M-07e
Resistant 1
Resistant 1_sgJAK2-1
Resistant 1_sgJAK2-2
Resistant 2
Resistant 2_sgJAK2-1
Resistant 2_sgJAK2-2
Dox - + + - + +
JAK2
Actin
Resistant_sgNT_D4
Resistant_sgNT_D7
Resistant_sgJAK2_1_D4
Resistant_sgJAK2_1_D7
Resistant_sgJAK2_2_D4
Resistant_sgJAK2_2_D7
Dox + + + + + +
D
Parental
Resistant
pSTAT3
STAT3
p-MEK1/2
MEK1/2
p-AKT
AKT
Vinculin